NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

Serina Therapeutics, Inc. (SER) Stock Analysis

Serina Therapeutics, Inc. (SER) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

SER

$2.73

+$0.04 (+1.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SER with… →

SER Key Statistics

As of Sep 4, 2026
Trading
Open
$2.70
Previous Close
$2.69
Day's Range
2.51–2.74
52-Week Range
1.22–5.83
Volume
14.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.09
Valuation
Market Cap
$69.34M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$19.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
25.40M
1-Year Return
−48.30%
Dividend and dates
Avg Volume
76.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SER Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+42.71%
2025−61.82%
2024−63.56%
2023−30.25%
2022−49.36%
2021−28.29%
2020−16.48%
2019−39.13%
2018 (partial year)+10.33%

As of September 4, 2026.

SER Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$19.18M—
2024$0.00−$11.14M—
2023$3.00M$5.27M175.6%
2022$500.00K−$2.68M−536.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$24.02M−$19.18M—
2024$0.00—−$17.05M−$11.14M—
2023$3.00M—−$3.13M$5.27M175.6%
2022$500.00K—−$2.27M−$2.68M−536.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SER Valuation vs Biotechnology Median

Median of 656 stocks
MetricSERBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Serina Therapeutics, Inc. (SER) is capitalised at $69.34M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

Over the past 52 weeks the price has ranged from $1.22 to $5.83. The most recent close on file for SER is $2.73, dated September 4, 2026. That is +$0.04 (+1.49%) against the previous close. The latest close sits 123.77% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $19.18M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.9.

Across the 4 fiscal years on file, revenue moves from $500.00K in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −48.30%. Measured over 5 years, that is −40.79% a year compounded. Beta against the wider market is reported at 0.09. Annualized volatility over the trailing 7 years is 132.72%.

Growth & Income

The record shows no dividend for SER.

2026 is still running; the price is +42.71% year to date. Across the complete calendar years on file, 2020 returned −16.48% and 2024 returned −63.56%. Of the 7 complete calendar years on file, 0 finished higher.

Peer Comparison

Serina Therapeutics, Inc. (SER) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Serina Therapeutics, Inc. SER $69.34M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Serina Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Serina Therapeutics, Inc.

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Visit website →